Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Phathom Pharmaceuticals, Inc. logo

Phathom Pharmaceuticals, Inc. (PHAT) Stock Ticker

NASDAQ: PHAT · Healthcare · Biotechnology
$7.30+3.11%
USD · as of 2026-09-28 · market cap $590.6M
Open PHAT in TickrDownload for iPhone

PHAT right now

Growing revenue 63% a year on 83% gross margins.
Options expect by Oct 6±13.2%
Options expect by Oct 29±27.4%
Priced in for Oct 29 earnings±27.4%
IV rank (30-day)28% · cheap
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full PHAT picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on PHAT
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

PHAT stock facts

Ticker symbolPHAT
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryBiotechnology
Market cap$590.6M
CEOSteven L. Basta
Employees371
HeadquartersFlorham Park, NJ, US
IPO date2019-10-25
Websitewww.phathompharma.com

What you can see for PHAT on Tickr

Live PHAT price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the PHAT report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Phathom Pharmaceuticals, Inc.?

The ticker symbol for Phathom Pharmaceuticals, Inc. is PHAT, listed on the NASDAQ Global Select.

What is PHAT?

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States,…

HomeExploreMarketLists
All pages